Pharmaceuticals, Biotechnology and Life Sciences
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits…
STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in…
EB Development rises above 90% threshold Paris, May 19, 2024 – 7:00 pm – Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible),…
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through…
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements…
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary…
Presented new preclinical data in non-human primates (NHP) for alpha-1 antitrypsin deficiency (AATD) and phenylketonuria (PKU), where RNA Gene Writer…
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with…
MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage…
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody’s Investor Services…